Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.

@article{Dahari2011HepatitisCV,
  title={Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.},
  author={Harel Dahari and J{\'e}r{\'e}mie Guedj and Alan S. Perelson and Thomas J. Layden},
  journal={Current hepatitis reports},
  year={2011},
  volume={10 3},
  pages={214-227}
}
In the last decade hepatitis C virus (HCV) kinetics has become an important clinical tool for the optimization of therapy with (pegylated)-interferon-α (IFN) and ribavirin (RBV). Mathematical models have generated important insights into HCV pathogenesis, HCV- host dynamics, and IFN and RBV's modes of action. Clinical trials with direct acting agents (DAAs… CONTINUE READING